Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sets New 12-Month Low – Here’s Why

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s share price hit a new 52-week low on Monday . The company traded as low as $26.59 and last traded at $26.68, with a volume of 29974 shares changing hands. The stock had previously closed at $27.05.

Wall Street Analyst Weigh In

Several research analysts recently commented on LKFT shares. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research lowered Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Royal Bank Of Canada lifted their price target on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 24th. UBS Group reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Finally, Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Down 0.3%

The company’s 50 day moving average price is $29.47 and its two-hundred day moving average price is $31.56. The stock has a market cap of $1.75 billion, a P/E ratio of -18.87 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The company had revenue of $1.06 billion for the quarter. As a group, equities research analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 2.1% during the third quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock valued at $1,072,000 after acquiring an additional 643 shares in the last quarter. Van ECK Associates Corp raised its stake in Lakefront Biotherapeutics American Depositary Shares by 61.6% in the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock worth $64,000 after buying an additional 750 shares in the last quarter. Two Sigma Investments LP raised its stake in Lakefront Biotherapeutics American Depositary Shares by 3.7% in the third quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock worth $778,000 after buying an additional 800 shares in the last quarter. State of Wyoming bought a new position in Lakefront Biotherapeutics American Depositary Shares in the second quarter worth approximately $28,000. Finally, Arax Advisory Partners raised its stake in Lakefront Biotherapeutics American Depositary Shares by 319.2% in the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock worth $76,000 after buying an additional 1,778 shares in the last quarter. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.